2025 Sequencing Tumor Board 2025 Sequencing Tumor Board - 7/24/2025

07/24/2025 at 07:00 AM to 07/24/2025 at 08:00 AM

Live Activity

Purpose:

This case conference offers a multidisciplinary approach to review cases for somatic tumor results as well as other biomarkers and patient specific factors are considered and discussed to find treatment options for patients with cancer that have limited treatment options. The cases presented are referred by the treating oncologist or surgeon once the results for their next-generation sequencing tests from their tumor are returned. The multidisciplinary review includes the oncologists, surgeons and additional experts in oncology, pharmacology, genetics and clinical trials to discuss the best treatment options for individual patients based on the genomic alterations present in their cancer along with other questions about diagnostics, prognostic implications, potential clinical trials, and best standard of care options.

Objectives:

1 Integrate a multidisciplinary approach into the development of plan of care

- 2 Identify social determinants that affect patient care for oncology patients
- 3 Discuss and analyze patient cases with the healthcare team
- 4 Develop strategies and a team approach to prevent complications from therapies

Target Audience:

Physician, Pharmacist, Pharmacy Technician

For successful completion:

- Attend education
- Complete evaluation

Accreditation & Credit Designation:

Accreditation



In support of improving patient care, Avera is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Education Credit Designation(s)



IPCE (Team-based): This activity was planned by and for the healthcare team, and learners will receive 1.00 IPCE credit(s) for learning and change.

IPCE CREDIT™

Medicine CME: Avera designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)^M. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

REMINDER

Attendance can be texted up to 24 hours after the activity





Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

Pharmacy CE: Avera designates this activity for 1.00 ACPE contact hour(s). Pharmacists and pharmacy technicians should claim only the credit commensurate with the extent of their participation in the activity. Credit will be uploaded to the NABP CPE Monitor[®] within 30 days after the activity completion. Per ACPE rules, Avera does not have access nor the ability to upload credits requested after the evaluation closes. It is the responsibility of the pharmacist or pharmacy technician to provide the correct information (NABP ID and DOB (MMDD)) to receive credit.

Additional Information:

• Feedback person for this educational activity is: rachel.elsey@avera.org, hannah.koble@avera.org

Disclosure Policy:

Due to the regulations required for CE credits, all conflicts of interest that persons in a position to control or influence the education must be fully disclosed to participants. In observance of this requirement, we are providing the following disclosure information: all relevant financial relationships disclosed below have been mitigated.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Benjamin Solomon, MD, Physician	Content Expert - Committee Member	Nothing to disclose - 04/28/2025
Rachel Elsey, PharmD, Pharmacist	Faculty, Lead Planner	Nothing to disclose - 09/17/2024
Hannah Koble	Proxy	Nothing to disclose - 08/27/2024
Il obias Meissner, PhD, Researcher	Content Expert - Committee Member	Nothing to disclose - 09/09/2024

